Butylated Hydroxytoluene vs Acesulfame Potassium: which is worse?

What is Butylated Hydroxytoluene?

Butylated hydroxytoluene (BHT) is a synthetic lipophilic phenolic antioxidant preservative derived from petroleum. It is a white crystalline solid with chemical formula C15H24O. Like BHA, it prevents fat oxidation and is widely used in food, cosmetics, pharmaceuticals, jet fuel, and rubber.

What is Acesulfame Potassium?

Acesulfame potassium (Ace-K) is a calorie-free synthetic sweetener approximately 200 times sweeter than sucrose. It contains a potassium atom bonded to an oxathiazinone dioxide ring structure. It is heat-stable and non-metabolized, passing through the body unchanged. Often blended with sucralose or aspartame to mask bitter aftertaste.

Documented risks

Butylated Hydroxytoluene: BHT's carcinogenicity profile is complex and bidirectional. Some NTP bioassays found liver tumors in female mice at high doses, while other studies suggested BHT might inhibit tumor initiation in certain contexts. A 1986 NTP bioassay found liver tumors in female mice but anti-carcinogenic effects in the rat forestomach — making BHT's net carcinogenicity uncertain. IARC has not formally classified BHT in a specific Group due to this conflicting evidence. The NTP notes that BHT's carcinogenicity data are complex. The 'Report on Carcinogens' does not currently list BHT, unlike BHA, but the NTP has noted inconclusive evidence. Potential endocrine disruption: a 2017 study in Environmental Science & Technology found BHT disrupted thyroid hormone levels in female rats. Multiple animal studies have demonstrated weak estrogenic effects. The American Academy of Pediatrics' 2018 policy statement on food additives mentioned BHT as a synthetic preservative warranting reduced childhood exposure. Kellogg's Frosted Flakes in the US contains BHT to preserve freshness; the European version uses mixed tocopherols (vitamin E) instead — a commercially meaningful difference demonstrating feasibility of substitution. Japan banned BHT for food use based on its precautionary approach. The EU restricts it with ADI-based maximum permitted levels.

Acesulfame Potassium: The safety database for Ace-K is considered less comprehensive than that for other sweeteners. Critics have argued that the original FDA approval studies from the 1970s-1980s were insufficient in quality and length to definitively establish long-term safety. The Center for Science in the Public Interest (CSPI) has petitioned for additional testing. Two rat studies found statistically significant increases in lung tumors (in male rats) and mammary tumors at high doses. Regulatory agencies have argued these doses far exceeded typical human exposure and attributed the tumor findings to other factors. However, the question of whether Ace-K's approval studies meet modern standards has been raised by independent researchers. A 2021 study in Cell found that Ace-K and other non-nutritive sweeteners altered gut microbiome composition and affected glucose tolerance in some human participants. Ace-K specifically was associated with changes in gut bacteria that correlated with glycemic effects. Neurological concerns: some animal studies suggest Ace-K may affect brain neurotransmitter systems. A 2013 study in PLoS ONE found that Ace-K consumption in pregnant mice altered offspring postnatal taste preference and increased weight gain, suggesting potential transgenerational effects. These findings were at doses exceeding typical human intake. Endocrine disruption potential has been raised in some in vitro studies, but comprehensive human data are lacking.